Therefore, we chose the FVB-YAC128 model to study the effect of QRX-704 treatment, despite the fact that it is characterized by a mild and slow phenotype with only moderately elevated caspase-6 activity compared with human HD (14, 16). The gene discussed is CASP6; the disease is Huntington disease.